BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koda M, Ueki M, Maeda Y, Mimura KI, Okamoto K, Matsunaga Y, Kawakami M, Hosho K, Murawaki Y. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res. 2004;29:18-23. [PMID: 15135342 DOI: 10.1016/j.hepres.2004.02.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-213. [PMID: 15713921 DOI: 10.1097/01.rvi.00001142592.89564.f9] [Cited by in Crossref: 130] [Cited by in F6Publishing: 31] [Article Influence: 8.1] [Reference Citation Analysis]
2 Solmi L, Nigro G, Roda E. Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma. World J Gastroenterol 2006;12:1098-104. [PMID: 16534852 DOI: 10.3748/wjg.v12.i7.1098] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
3 Montorsi M, Santambrogio R, Bianchi P, Donadon M, Moroni E, Spinelli A, Costa M. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg. 2005;9:62-67; discussion 67-68. [PMID: 15623446 DOI: 10.1016/j.gassur.2004.10.003] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
4 Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007;41:839-54. [DOI: 10.1097/mcg.0b013e318060ac52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
5 Lee HS, Park SY, Kim SK, Kweon YO, Tak WY, Cho CM, Jeon SW, Jung MK, Park HG, Lee DW. Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2012;18:302-308. [PMID: 23091811 DOI: 10.3350/cmh.2012.18.3.302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
6 Kuroda H, Kasai K, Kakisaka K, Yasumi Y, Kataoka K, Ushio A, Miyamoto Y, Sawara K, Oikawa K, Kondo K. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatol Res. 2010;40:550-554. [PMID: 20546330 DOI: 10.1111/j.1872-034x.2009.00613.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
7 Lee S, Jeong WK, Rhim H. Repeated percutaneous radiofrequency ablation for hepatocellular carcinoma in patients with cirrhosis: assessment of safety based on liver function and portal hypertension parameters. J Vasc Interv Radiol. 2014;25:1573-1579. [PMID: 25108816 DOI: 10.1016/j.jvir.2014.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Honda K, Seike M, Oribe J, Endo M, Arakawa M, Syo H, Iwao M, Tokoro M, Nishimura J, Mori T, Yamashita T, Fukuchi S, Muro T, Murakami K. Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy. World J Hepatol 2016;8:597-604. [PMID: 27168872 DOI: 10.4254/wjh.v8.i13.597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW, Burroughs AK. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594-606. [PMID: 17045407 DOI: 10.1016/j.ctrv.2006.08.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
10 Madoff DC, Denys A, Wallace MJ, Murthy R, Gupta S, Pillsbury EP, Ahrar K, Bessoud B, Hicks ME. Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. Radiographics. 2005;25 Suppl 1:S191-S211. [PMID: 16227491 DOI: 10.1148/rg.25si055504] [Cited by in Crossref: 167] [Cited by in F6Publishing: 93] [Article Influence: 11.1] [Reference Citation Analysis]
11 Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623-1641. [PMID: 18925854 DOI: 10.1586/14737140.8.10.1623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
12 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Li JX, Wu H, Huang JW, Zeng Y. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formos Med Assoc. 2012;111:510-515. [PMID: 23021508 DOI: 10.1016/j.jfma.2011.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
14 Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2014;20:12588-12594. [PMID: 25253962 DOI: 10.3748/wjg.v20.i35.12588] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
15 Kong WT, Zhang WW, Qiu YD, Zhou T, Qiu JL, Zhang W, Ding YT. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol 2009;15:2651-6. [PMID: 19496197 DOI: 10.3748/wjg.15.2651] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
16 Ishihara T, Iwasa M, Tanaka H, Kaito M, Ikoma J, Shibata T, Takei Y. Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma. World J Gastroenterol 2014;20:2673-80. [PMID: 24627603 DOI: 10.3748/wjg.v20.i10.2673] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Morimoto M, Numata K, Nozaki A, Tanaka K. Prognosis following non-surgical second treatment in patients with recurrent hepatocellular carcinoma after percutaneous ablation therapy. Liver International 2009;29:443-8. [DOI: 10.1111/j.1478-3231.2008.01890.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Satiya J, Schwartz I, Tabibian JH, Kumar V, Girotra M. Ablative therapies for hepatic and biliary tumors: endohepatology coming of age. Transl Gastroenterol Hepatol 2020;5:15. [PMID: 32258519 DOI: 10.21037/tgh.2019.10.17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
19 Pua BB, Sofocleous CT. Imaging to optimize liver tumor ablation. Imaging Med 2010;2:433-43. [PMID: 27840657 DOI: 10.2217/IIM.10.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
20 Boninsegna E, Simonini E, Crosara S, De Angelis M, Boccia L, Colopi S. Large Multifocal Hepatocarcinoma: Technical Details of Treatment with Combined Transarterial Chemoembolization, Microwave and Radiofrequency Ablation. J Gastrointest Cancer 2021;52:300-5. [PMID: 32436050 DOI: 10.1007/s12029-020-00416-w] [Reference Citation Analysis]
21 Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, Chi KH. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol 2021;16:18. [PMID: 33472666 DOI: 10.1186/s13014-020-01742-w] [Reference Citation Analysis]
22 Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137. [PMID: 15841454 DOI: 10.1002/hep.20688] [Cited by in Crossref: 244] [Cited by in F6Publishing: 219] [Article Influence: 15.3] [Reference Citation Analysis]
23 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 45] [Article Influence: 12.9] [Reference Citation Analysis]
24 Kim W, Cho SK, Shin SW, Hyun D, Lee MW, Rhim H. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdom Radiol (NY). 2019;44:2283-2292. [PMID: 30806742 DOI: 10.1007/s00261-019-01952-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 20.0] [Reference Citation Analysis]
25 Seror O, N’kontchou G, Muhammad M, Barrucand C, Tin Tin Htar M, Assaban M, Haddar D, Trinchet J, Beaugrand M, Sellier N. Influence de la proximité des gros vaisseaux sur les résultats du traitement des carcinomes hépato-cellulaires par radiofréquence : une étude contrôlée. Journal de Radiologie 2007;88:1157-64. [DOI: 10.1016/s0221-0363(07)89927-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]